Is pharma exploiting regulatory loopholes to avoid pediatric cancer trials?
This article was originally published in Scrip
Executive Summary
Children with cancer are being denied access to new oncology treatments because of a loophole in the European Union's Regulation on Paediatric Medicine, claims the Institute of Cancer Research (ICR), a leading UK-based research organization.